The review further distinguishes between established outcome benefits (CVD, CKD, and OSA) and conditions still under investigation (neurodegeneration, arthritis, and some liver endpoints)
Larger outsourcing pharmacies making compound versions of Zepbound have until March 19 to stop, according to the FDA
Non-Diabetes Specialists Drive New Growth in GLP-1 Prescriptions Patients with Type 2 diabetes (T2D) and obesity often present with multiple comorbidities spanning a wide range of diseases, requiring care from diverse specialists
Many health plans, including Medicare, do not currently cover drugs prescribed for obesity management
While gradual dose titration is common, using GLP-1s at micro-doses specifically for menopause is currently unapproved and the long-term risks are unknown